Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses

The article discussed the main treatment strategy for patients with platinum-sensitive relapsed the high-grade serous cancer of the ovaries, fallopian tube cancer and primary peritoneal cancer. The commonality of these tumors is caused by the same type of coelomic epithelium of mesodermal origin of the rudiments of Müllerian ducts, as well as similarities in the ways of carcinogenesis: the loss or inactivation of the tumor suppressor TP53, loss of function of proteins BRCA1 and BRCA2 – the controllers of DNA repair and genome integrity. Platinum drugs and PARP inhibitors have priority in treatment – “BRCA-associated” cancers. Maintenance monotherapy with the PARP inhibitor olaparib after platinum prolonged by 7 months progression-free survival. Olaparib will be to benefit patients with a BRCA mutation. Search mutations in the genes BRCA1 and BRCA2 of all high-grade ovarian cancer patients, allow to allocate patients with relapses requiring therapy resumed platinum drugs and continued the PARP inhibitor olaparib. In these cases, Lynparza (olaparib) 400 mg twice daily, as maintenance treatment in patients with platinum-sensitive relapse who had received two or more platinum-based regimens and who had a partial or complete response to their most recent platinum-based regimen and with BRCA-mutation have the greatest likelihood of benefiting from olaparib maintenance treatment.

high grade serous ovarian cancer, chemotherapy, platinum-sensitive relapse, BRCA-associated ovarian cancer, ovarian cancer genetics, hereditary ovarian cancer, olaparib, PARP inhibitors